Campbell & CO Investment Adviser LLC Grows Stake in Boston Scientific Corporation $BSX

Campbell & CO Investment Adviser LLC grew its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 644.9% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 17,267 shares of the medical equipment provider’s stock after acquiring an additional 14,949 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Boston Scientific were worth $1,686,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of BSX. Brighton Jones LLC raised its stake in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after buying an additional 226 shares during the period. Pallas Capital Advisors LLC increased its holdings in Boston Scientific by 52.9% in the 2nd quarter. Pallas Capital Advisors LLC now owns 6,163 shares of the medical equipment provider’s stock worth $662,000 after acquiring an additional 2,132 shares during the last quarter. Exchange Traded Concepts LLC raised its stake in Boston Scientific by 279.0% in the 2nd quarter. Exchange Traded Concepts LLC now owns 41,872 shares of the medical equipment provider’s stock valued at $4,497,000 after acquiring an additional 30,824 shares during the period. Redhawk Wealth Advisors Inc. lifted its holdings in Boston Scientific by 11.7% during the second quarter. Redhawk Wealth Advisors Inc. now owns 4,734 shares of the medical equipment provider’s stock valued at $508,000 after purchasing an additional 495 shares during the last quarter. Finally, Oliver Lagore Vanvalin Investment Group bought a new position in Boston Scientific during the second quarter worth about $37,000. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on BSX. Barclays upped their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Wells Fargo & Company raised their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. BTIG Research restated a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a research note on Friday, November 21st. Canaccord Genuity Group cut their price target on shares of Boston Scientific from $132.00 to $131.00 and set a “buy” rating for the company in a research note on Wednesday, December 17th. Finally, Royal Bank Of Canada raised their price objective on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $123.89.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Acquisition expands addressable market — The agreement to buy Penumbra (~$14.5B enterprise value) gives Boston Scientific scaled entry into mechanical thrombectomy and neurovascular devices, which management says accelerates growth in fast-growing vascular segments. Read More.
• Positive Sentiment: Wall Street support remains — TD Cowen reiterated a Buy and other analysts emphasize the deal as a strategic growth catalyst and valuation support ahead of 2026 expectations. Read More.
• Neutral Sentiment: Price-target and analyst notes are mixed — Oppenheimer trimmed its target from $125 to $100 but kept an Outperform rating, indicating continued upside though with more cautious near-term expectations. Read More.
• Neutral Sentiment: Technical/turnaround commentary — Some market commentators note BSX is technically oversold and that consensus earnings revisions are turning positive, which could support a rebound over time. Read More.
• Neutral Sentiment: Smaller tuck-ins continue — Boston Scientific’s other recent deals (e.g., Valencia Technologies) broaden product offerings in urology and ITNS, a modest near-term boost versus the Penumbra scale. Read More.
• Negative Sentiment: Shares sold off on the deal announcement — The market reacted negatively to the size/structure of the transaction and near-term uncertainty, and BSX shares traded down after the news. Read More.
• Negative Sentiment: Legal/approval uncertainty — Law firms have launched investor inquiries into the adequacy of Penumbra’s sale process and price; this increases deal execution risk and could prolong integration or regulatory review. Read More.
• Negative Sentiment: Derivative-market hedging and bearish interest spiked — Unusually large put option volume indicates some investors are hedging or betting on further downside, adding volatility risk. Read More.
• Negative Sentiment: Mixed analyst commentary and skeptic pieces — Several independent commentaries and Seeking Alpha pieces highlight concerns about price paid and strategic fit, underscoring near-term skepticism despite long-term promise. Read More.

Boston Scientific Trading Down 2.1%

Shares of BSX opened at $88.13 on Friday. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50. The firm has a market cap of $130.65 billion, a price-to-earnings ratio of 47.13, a PEG ratio of 1.56 and a beta of 0.67. The firm has a 50 day moving average price of $96.90 and a 200-day moving average price of $100.29. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter last year, the company earned $0.63 EPS. The firm’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,739,678.74. The trade was a 21.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 93,095 shares of company stock worth $9,305,450 in the last ninety days. 0.50% of the stock is owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.